A Canadian population-based study has confirmed that people with cancer have an increased risk of breakthrough COVID-19 infection after vaccination, while UK research points to the feasibility of SARS-CoV-2 antibody testing to identify those with the lowest level of vaccine-derived protection.

Results of a large systematic review and meta-analysis show that people with cancer have a significantly greater risk for death from SARS-CoV-2 infection than their cancer-free peers, particularly if they have lung or hematologic cancer.

TERAVOLT registry investigators have identified seven major risk factors for COVID-19 mortality in patients with thoracic malignancy, with poor ECOG performance status the strongest prognostic marker.

Research from three countries adds support for the use of a booster dose of vaccines against SARS-CoV-2 in people with cancer, especially those undergoing active anticancer treatment.

Around one in seven people with cancer and COVID-19 report persistent symptomatic sequelae of the infection after recovery, suggest data from the OnCovid study.

COVID-19 vaccination reduces the risk for SARS-CoV-2 infection and associated mortality in people with cancer, although two doses are necessary for maximum protection, reports a French research team.

Around a fifth of people with cancer included in the French COVIPACT study reported symptoms consistent with post-traumatic stress disorder during the first national lockdown in response to the COVID-19 outbreak, find the investigators.

The COVID-19 Vaccination Advisory Committee of the US National Comprehensive Cancer Network has provided preliminary recommendations for COVID-19 vaccinations in people with cancer.

Patients with cancer may show a weaker immune response to COVID-19 vaccines, compared to the general population.

A single dose of the Pfizer-BioNTech vaccine induces high SARS-CoV-2 antibody levels in people with cancer and prior SARS-CoV-2 infection, but immunogenicity is lower in those without previous infection, research shows.

French researchers report a low seroconversion rate after one dose of the COVID-19 mRNA vaccine among people with cancer.

Two independent studies presented at the IASLC 2020 World Conference on Lung Cancer have highlighted the heightened psychological distress experienced by patients with cancer – especially those with lung cancer – during the COVID-19 pandemic.

Results from the COVID-19 and Cancer Consortium show that a variety of treatments for COVID-19 have no significant positive impact on 30-day mortality in patients with invasive cancer.